Group items tagged

The purpose of this Funding Opportunity Announcement (FOA) is to build upon the work that has begun under previous FOA RFA-TR-17-007 NCATS Pilot Program for Collaborative Drug Discovery Research Using Bioprinted Skin Tissue and utilize physiologically relevant and validated 3-D biofabricated skin disease tissue models in multi-well drug screening platforms. The FOA will support intramural- extramural collaborations to implement the use of 3-D biofabricated skin tissue models and provide evidence of success for 3-D drug screening platforms.

The ReVector program aims to develop methods to use human skin microbiomes to modulate chemical signatures in order to avoid mosquito attraction and feeding and reduce the threat of mosquito-borne disease to Warfighters. Human skin associated microbes interact with metabolites from the body and influence the personal chemical signature of each individual, making some individuals more attractive to mosquitoes. This program seeks to develop advanced data analytics and microbiome modulation tools for engineering skin microbiomes and provide new options for the readiness and resiliency of military personnel.

The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) requests applications for the NIAMS Core Centers for Clinical Research (CCCR) (P30) within its mission. The CCCRs will provide avenues to advance the methodological sciences that support clinical research within and across the NIAMS' portfolio of diseases. The overall goals of the CCCR are to advance prevention, diagnosis and treatment of musculoskeletal, rheumatologic, and skin diseases by developing and fostering the implementation of novel methods, metrics, and outcome measures that address critical existing and emerging clinical research needs. 

The purpose of this funding opportunity is to support the research and development necessary to advance spectroscopic imaging technologies, methods, study designs, and analyses to non-invasively measure the rate and extent to which a topically applied compound becomes available in the epidermis, at or near a site of action within the skin. The expectation is that the funded work will produce an accurate, sensitive and reproducible approach that measures the amount of drug present in the epidermis at each of a series of depths below the skin surface, which can be utilized to monitor epidermal pharmacokinetics by repeated measurements over time.

This Funding Opportunity Announcement (FOA) is to encourage Research Project Grant (R01) applications to pursue clinical observational (CO) studies to obtain data necessary for designing clinical studies for musculoskeletal, rheumatic, or skin diseases or conditions. A future clinical study may include a clinical trial or an observational study. Research data from observational studies supported by this FOA can enhance clinical study design by providing essential information about disease symptoms, stages and timing of disease progression, comorbid conditions, availability of potential research participants, and outcomes that are important to patients. They also can facilitate efforts to develop and/or validate objective biomarkers or subjective outcome measures for use in a future clinical study. Applicants to this FOA are encouraged to propose studies that address significant obstacles or questions in the design of a clinical project, such as determining the appropriate primary or secondary outcome measures, or identifying the stages of disease during which patients are most likely to respond to an intervention. Only observational studies will be supported through this FOA.

The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) requests applications for the NIAMS Resource-based Centers Program (P30) for research areas within its mission in musculoskeletal biology and medicine. The Resource-based Centers will provide critical research infrastructure, shared facilities, services, and/or resources to groups of investigators conducting research on musculoskeletal biology and medicine, enabling them to conduct their independently-funded individual and/or collaborative research projects more efficiently and/or more effectively, with the broad overall goal of accelerating, enriching, and enhancing the effectiveness of ongoing basic, translational, and clinical research and promoting new research within the NIAMS mission.

NineSigma, representing Betco Corporation, a privately held specialty chemical and equipment manufacturer, is seeking partners with solutions to clean, disinfect, and sanitize skin and surfaces. Novel products, technology advancements, or other approaches that can demonstrate efficacy to improve the overall cleanliness, health, and safety of commercial environments are of immediate interest.

LEO Foundation 'Open competition grants' are given to support the best dermatology research projects worldwide. Thus, we welcome applications from research projects that: - Improve the understanding of the underlying medicinal, biological, chemical, or pharmacological mechanisms of dermatological diseases and their symptoms - Address clinical issues among people who are at risk of developing, or have developed, a skin disease, including how it impacts their quality of life and the societal costs involved